Emergent BioSolutions, already flush with products against public health threats like anthrax attacks and opioid overdoses, is expanding its arsenal of medical countermeasures by scooping up global rights to smallpox newcomer Tembexa.
Emergent will furnish developer Chimerix with $225 million in upfront cash plus upward of $100 million in milestone payments for worldwide rights to the med, also known as brincidofovir. The drug last summer snagged FDA approval as the first antiviral cleared to treat smallpox regardless of a patient’s age.
{iframe}https://www.fiercepharma.com/pharma/emergent-beefs-countermeasure-repertoire-325m-deal-chimerixs-smallpox-newcomer-tembexa{/iframe}